financetom
Market
financetom
/
Market
/
Traders Eye Start to Q3 Earnings Season as US Equity Futures Drop Pre-Bell
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Traders Eye Start to Q3 Earnings Season as US Equity Futures Drop Pre-Bell
Oct 7, 2024 6:16 AM

08:53 AM EDT, 10/07/2024 (MT Newswires) -- US equity futures fell ahead of Monday's opening bell as the Q3 earnings season gets underway.

The Dow Jones Industrial Average futures fell 0.4%, S&P 500 futures dropped 0.4% and Nasdaq futures were down 0.5%.

Pepsico ( PEP ) is scheduled to report earnings on Tuesday before banking majors JPMorgan ( JPM ) and Wells Fargo ( WFC ) formally kick off the earnings season on Friday.

Oil prices were higher, with front-month global benchmark North Sea Brent crude up 1% at $78.84 per barrel and US West Texas Intermediate crude up 1.1% at $75.22 per barrel.

Consumer credit, due for release at 3 pm ET, is expected to drop to $11.8 billion in August from $25.45 billion in the preceding month, according to estimates compiled by Bloomberg.

In other world markets, Japan's Nikkei closed 1.8% higher, Hong Kong's Hang Seng ended 1.6% higher, while the Chinese market was closed for holiday. Across the Atlantic, UK's FTSE 100 gained 0.4%, and Germany's DAX index fell 0.2% in Europe's early afternoon session.

In equities, shares of Pfizer ( PFE ) were 2.9% higher pre-bell after media outlets reported that the drugmaker may become the target of a shareholder campaign led by activist investor Starboard Value. Duckhorn Portfolio ( NAPA ) shares more than doubled after the company agreed to be acquired by Butterfly Equity in a deal worth $1.95 billion.

On the losing side, Mullen Automotive ( MULN ) shares fell 5.6% after the company unveiled a cost cutting plan that includes a 20% headcount reduction. Trevena ( TRVN ) shares retreated 48% after the company said late Friday it received a delisting notice from Nasdaq with trading of its shares to be suspended effective Tuesday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Tech
Sector Update: Tech
Oct 7, 2024
08:45 AM EDT, 10/07/2024 (MT Newswires) -- Technology stocks were declining pre-bell Monday as the Technology Select Sector SPDR Fund (XLK) was down 0.5% and the SPDR S&P Semiconductor ETF (XSD) was 0.2% lower recently. EPAM Systems ( EPAM ) shares fell by 4% after the company said it struck a deal to acquire First Derivative, a managed services and...
Traders Eye Start to Q3 Earnings Season as US Equity Futures Drop Pre-Bell
Traders Eye Start to Q3 Earnings Season as US Equity Futures Drop Pre-Bell
Oct 7, 2024
08:53 AM EDT, 10/07/2024 (MT Newswires) -- US equity futures fell ahead of Monday's opening bell as the Q3 earnings season gets underway. The Dow Jones Industrial Average futures fell 0.4%, S&P 500 futures dropped 0.4% and Nasdaq futures were down 0.5%. Pepsico ( PEP ) is scheduled to report earnings on Tuesday before banking majors JPMorgan ( JPM )...
Upcoming Start to Q3 Earnings Season Drive Premarket Losses for US Equity Futures
Upcoming Start to Q3 Earnings Season Drive Premarket Losses for US Equity Futures
Oct 7, 2024
08:10 AM EDT, 10/07/2024 (MT Newswires) -- US equity futures were lower pre-bell Monday as the Q3 earnings season gets underway. The Dow Jones Industrial Average futures fell 0.4%, S&P 500 futures dropped 0.5% and Nasdaq futures were down 0.6%. Pepsico ( PEP ) is scheduled to report earnings on Tuesday before banking majors JPMorgan ( JPM ) and Wells...
Sector Update: Health Care
Sector Update: Health Care
Oct 7, 2024
08:54 AM EDT, 10/07/2024 (MT Newswires) -- Health care stocks were steady premarket Monday with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) recently inactive. Scholar Rock Holding ( SRRK ) shares surged past 235% after the company said a phase 3 trial of its investigational therapy apitegromab in patients with spinal muscular atrophy met...
Copyright 2023-2025 - www.financetom.com All Rights Reserved